Aether Industries (AETHER) Q4 22/23 earnings summary

Executive summary

• FY23 revenue from operations rose 10.34% YoY to ₹6,510.74 MM; profit after tax increased 19.73% to ₹1,304.17 MM.

• Growth came from CRAMS and Contract/Exclusive Manufacturing, offsetting weaker Large Scale Manufacturing amid a first-half pharmaceutical slowdown.

• Expansion and R&D investment accelerated: Site 3 began commercial production, and R&D and Pilot Plant capacity tripled.

Financial highlights

• Total income was ₹6,676.39 MM versus ₹5,970.21 MM in FY22; revenue from operations was ₹6,510.74 MM versus ₹5,900.47 MM.

• Profit before tax increased 19.12% YoY to ₹1,744.79 MM; PAT rose 19.73% to ₹1,304.17 MM.

• Other income increased 137.53% to ₹165.65 MM, including ₹74.23 MM interest on fixed deposits funded with IPO proceeds.

• Finance costs fell 61.18% to ₹50.93 MM after term-loan repayment and closure of working-capital limits using IPO proceeds.

• EBITDA is presented on differing bases: ₹2,028.16 MM and 30.38% margin in highlights; ₹1,862.51 MM and 28.61% using the MD&A reconciliation excluding other income.

Outlook and guidance

• Management expected pharmaceutical demand to return to historically normal levels after recovery from mid-Q3, with Q4 demand near normal; demand was described as strong in the final two quarters.

• Management anticipated continued growth in CRAMS and Contract/Exclusive Manufacturing, citing rising inquiries, customer additions, contract renewals and business conversion.

• Site 3’s five products were to be phased in; three launched in January 2023, with the remaining two planned for April/May 2023.

• Site 4 planning and initial development were advancing; Site 5 at Panoli was acquired for future expansion, with regulatory approvals and preparatory work underway.

• AGM proposals sought approval for raising up to ₹7,500 MM through permitted securities and increasing authorized equity capital to ₹1,475 MM; these were proposals, not completed financing.